NASDAQ: IRON - Disc Medicine Opco Inc

Rentabilität für sechs Monate: -16.09%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Disc Medicine Opco Inc

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Disc Medicine Opco Inc

Disc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria.

weitere details
In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2020-08-12
ISIN US2546041011
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.discmedicine.com
Цена ао 52.49
Preisänderung pro Tag: 0% (40.27)
Preisänderung pro Woche: +17.47% (34.28)
Preisänderung pro Monat: -21.07% (51.02)
Preisänderung über 3 Monate: -30.36% (57.83)
Preisänderung über sechs Monate: -16.09% (47.99)
Preisänderung pro Jahr: +34.55% (29.93)
Preisänderung über 3 Jahre: +890.65% (4.065)
Preisänderung seit Jahresbeginn: -36.03% (62.95)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 4.27 4
P/E 0 0
EV/EBITDA -11.02 0
Gesamt: 2.25

Effizienz

Name Bedeutung Grad
ROA, % -25.29 0
ROE, % -27.73 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.3296 10
Gesamt: 9.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 170.1 10
Rentabilität EPS, % -86.45 0
Gesamt: 6
Weitere Details

Institutionen Volumen Aktie, %
Atlas Venture Life Science Advisors, LLC 2745335 11.37
Orbimed Advisors LLC. 2269637 9.4
Bain Capital Life Sciences Investors, LLC 1332545 5.52
Adage Capital Partners GP L.L.C. 1308405 5.42
Paradigm Biocapital Advisors LP 1272279 5.27
Novo Holdings A/S 1090772 4.52
Perceptive Advisors LLC 895641 3.71
State Street Corporation 667301 2.76
Vanguard Group Inc 665452 2.76
Frazier Life Sciences Management, L.P. 655000 2.71

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Future Tech ETF 0.13875 426.34 0.8416
Principal Healthcare Innovators ETF 0.13875 618.5 0.8416
iShares Morningstar Small-Cap ETF 0.01136 391.25 1.60498
0.1478.71.09



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Donald William Nicholson Ph.D. Executive Chairman 164k 1958 (67 Jahre)
Dr. John D. Quisel Esq., J.D., Ph.D. CEO, President & Director 750.12k 1971 (54 Jahr)
Dr. William Jacob Savage M.D., Ph.D. Chief Medical Officer 687.74k 1974 (51 Jahr)
Dr. Brian MacDonald ChB, MB, Ph.D. Founder & Chair of Scientific Advisory Board 88.54k 1960 (65 Jahre)
Dr. Rahul Khara J.D., Pharm.D. General Counsel, Compliance Officer & Secretary N/A 1982 (43 Jahr)
Mr. Srikanth Venkatraman Ph.D. Senior VP & Head of Chemistry N/A
Ms. Hua Yang Ph.D. Senior Vice President & Head of Early Development and Clinical Pharmacology N/A
Ms. Jean M. Franchi Chief Financial Officer N/A 1966 (59 Jahre)
Mr. Jonathan Yu M.B.A. Chief Opearating Officer 539.32k 1981 (44 Jahr)
Ms. Pamela Stephenson M.P.H. Chief Commercial Officer N/A 1968 (57 Jahre)

Adresse: United States, Watertown. MA, 321 Arsenal Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.discmedicine.com